# DeepHealth

> DeepHealth is RadNet’s wholly owned AI and imaging informatics business. It combines clinical tools for breast, chest, prostate, neurological, thyroid and musculoskeletal imaging with software for scheduling, remote scanning, image management and reporting, serving healthcare providers internationally.

- **Founded:** 2015
- **Headquarters:** Somerville, United States
- **Founders:** A. Gregory Sorensen (Co-founder and original President), Bill Lotter (Co-founder and original CTO)
- **Products:** DeepHealth OS, Diagnostic Suite, Operations Suite, TechLive, Breast Suite
- **Notable:** TechLive FDA clearance in 2025 and CE marking announced February 2026., A July 2026 Radiology study evaluated more than 577,000 screening mammograms across 109 sites and reported higher adjusted cancer detection among general radiologists, with higher recall rates., FDA clearance for Breast Ultrasound announced July 2026.

## Products & services

- **DeepHealth OS** — Cloud-native foundation connecting clinical and operational imaging data.
- **Diagnostic Suite** — Image management, PACS functionality, diagnostic viewing and AI orchestration.
- **Operations Suite** — RIS-based scheduling, registration, patient communication, billing and analytics.
- **TechLive** — Vendor-agnostic remote imaging supervision and collaboration across multiple modalities; FDA-cleared in 2025 and CE-marked in 2026.
- **Breast Suite** — Modular mammography detection, density, risk and review workflows, including Mammo Dx and Safeguard Review.
- **Prostate Suite** — MRI lesion detection, segmentation, reporting and fusion-biopsy handoff; new Prostate AI clearance announced May 2026.
- **Chest Suite** — Pulmonary nodule detection, quantification, reporting and longitudinal tracking.
- **Neuro Suite** — Brain Health and Brain Age automate white-matter and brain-volume measurements.
- **Thyroid Suite** — AI-assisted thyroid ultrasound measurement, characterization and reporting.
- **Reporting Pro** — Speech recognition, AI findings, measurements, draft impressions and quality assurance in a clinician-reviewed reporting workflow.
- **Breast Ultrasound** — Lesion detection, characterization and reporting; FDA clearance announced July 2026.
- **Chest XRay** — Detects and localizes suspected thoracic abnormalities using technology acquired with Gleamer; FDA clearance announced September 2026.

## Achievements

- TechLive FDA clearance in 2025 and CE marking announced February 2026.
- A July 2026 Radiology study evaluated more than 577,000 screening mammograms across 109 sites and reported higher adjusted cancer detection among general radiologists, with higher recall rates.
- FDA clearance for Breast Ultrasound announced July 2026.
- FDA clearance for Chest XRay announced September 2026.

## Latest updates

- **2026-09** — September 16: FDA clearance announced for Chest XRay, commercially available in the US and Europe.
- **2026-08** — RadNet reported Q2 Digital Health revenue of $32.4 million and June-end ARR of $105.5 million.
- **2026-07** — Breast Ultrasound FDA clearance announced July 30; July 27 study summary reported improved generalist cancer detection and increased recalls.
- **2026-06** — Reporting Pro launched commercially June 10 in the US and UK.
- **2026-03** — Gleamer acquisition announced March 2, with purchase price up to €230 million including a milestone.

## Links

- Website: https://deephealth.com/
- LinkedIn: https://www.linkedin.com/company/deephealthai/

---

Profile page: https://yespress.io/deephealth
Published by YesPress — https://yespress.io
Last updated: 2026-09-30